Company news

Alkermes plc news in 2026

Alkermes plc's news releases, calls and decks from 2026, newest first.

View company

Alkermes to Present at Upcoming Investor Conferences

November 3, 2026

Alkermes plc Reports Third Quarter 2026 Financial Results

November 3, 2026

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

October 30, 2026

Alkermes to Report Third Quarter Financial Results on November 3, 2026

October 20, 2026

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

October 13, 2026

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

September 21, 2026

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

September 16, 2026

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

September 10, 2026

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

August 24, 2026

Alkermes plc Reports Second Quarter 2026 Financial Results

July 28, 2026

Alkermes to Report Second Quarter Financial Results on July 28, 2026

July 14, 2026

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

July 13, 2026

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

June 17, 2026

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

June 15, 2026

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

June 4, 2026

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

May 26, 2026

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

May 21, 2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

May 12, 2026

Alkermes plc Reports First Quarter 2026 Financial Results

May 5, 2026

Alkermes to Report First Quarter Financial Results on May 5, 2026

April 21, 2026

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

April 16, 2026

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

April 14, 2026

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

March 31, 2026

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

March 11, 2026

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

March 9, 2026

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

February 24, 2026

Alkermes plc Announces CEO Succession Plan

February 24, 2026

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

February 12, 2026

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

February 11, 2026

Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes

January 12, 2026

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

January 6, 2026

Calls in 2026

Decks in 2026